Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 10, 26 | Wadors Patricia L | officer: SVP Chief Human Resources Offi | M-Exempt | 2,140 | — |
Daily · Wilder smoothing
| Oct 10, 26 |
| Wadors Patricia L |
| officer: SVP Chief Human Resources Offi |
| M-Exempt |
| 2,140 |
| — |
| Oct 10, 26 | Wadors Patricia L | officer: SVP Chief Human Resources Offi | F-InKind | 1,062 @ $423.96 | $450.2K |
| Oct 10, 26 | Loeb Gary | officer: EVP & Chief Legal and Complian | M-Exempt | 2,612 | — |
| Oct 10, 26 | Loeb Gary | officer: EVP & Chief Legal and Complian | F-InKind | 1,296 @ $423.96 | $549.5K |
| Oct 10, 26 | Loeb Gary | officer: EVP & Chief Legal and Complian | M-Exempt | 2,612 | — |
| Sep 15, 26 | Widman Fredrik | officer: VP Corporate Controller | M-Exempt | 546 @ $79.64 | $43.48K |
| Sep 15, 26 | Widman Fredrik | officer: VP Corporate Controller | M-Exempt | 543 @ $109.49 | $59.45K |
Classic floor pivots from 2026-10-19
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 67.68 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 91.05 | Oscillator | Sell |
| Williams %R (14) | -3.74 | Oscillator | Sell |
| MACD (12, 26, 9) | 11.30 (Hist 1.27) | Oscillator | Strong Buy |
| Average Directional Index (14) | 16.46 (+DI 23.6 / -DI 13.8) | Trend | Neutral |
| EMA 20 | 412.73 | MA | Strong Buy |
| SMA 20 | 412.73 | MA | Strong Buy |
| EMA 50 | 400.20 | MA | Strong Buy |
| SMA 50 | 392.76 | MA | Strong Buy |
| SMA 200 | 438.97 | MA | Sell |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Stock news · updated daily
UVE, HAS, TXN, URI and ISRG have been added to the Zacks Rank #1 (Strong Buy) List on October 23, 2026.
Cadinha and Co. LLC decreased its stake in shares of Intuitive Surgical, Inc. (NASDAQ: ISRG) by 44.2% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 28,413 shares of the medical equipment provider's stock after selling 22,531 shares during the
Ark Invest bought into some market laggards on Wednesday.
Intuitive Surgical NASDAQ: ISRG shocked the market by reporting not one but two margin impairments in its Q3 results, but investors shouldn't misread this.
Intuitive Surgical (NASDAQ: ISRG - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at BTIG Research in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $454.00 price target on the medical equipment provider's stock. BTIG Research's price target would suggest a potential upside of 6.05%
Intuitive Surgical (ISRG) and Elevance Health (ELV) delivered impressive Q3 earnings beats, making both healthcare stocks worth considering as their growth outlooks improve.
Intuitive Surgical's Q3 earnings call highlights instrument price cuts to boost robotic surgery adoption, higher 2026 margins and slowing U.S. procedure growth.
Total surgical procedures grew 15% year over year in the third quarter. Instrument price reductions will lower procedure revenue by 3% to 5%.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 16, 2026 | 2.51 | 2.80 | Beat 11.6% | $2.89B |
| Apr 21, 2026 | 2.51 | 2.80 | Beat 11.6% | $2.77B |
| Jan 22, 2026 | 2.27 | 2.53 | Beat 11.5% | $2.87B |
| Oct 21, 2025 | 1.99 | 2.40 | Beat 20.6% | $2.51B |
| Jul 22, 2025 | 1.93 | 2.19 | Beat 13.5% | $2.44B |
| Apr 22, 2025 | 1.74 | 1.81 | Beat 4.0% | $2.25B |
TTM vs. 5-year historical average (annual ratios)
| Metric | ISRG | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 48.9x | 72.6x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 40.1x | EPS est. 10.80 | Discount |
| Price / Book | 8.5x | 10.2x | Discount |
| Price / Sales | 13.9x | 19.3x | Discount |
| EV / EBITDA | 33.1x | 52.2x | Discount |
| Return on equity | 17.8% | — | Healthy |
| Gross margin | 66.7% | 67.3% | In line |
| Debt / Equity | 0.00 | 0.01 | Conservative |
| Piotroski / Altman Z | 7/9 | Z 37.62 | Safe zone |
Discounted cash flow model
Current price $433.18
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 12, 26 | BTIG | maintain | Buy | Buy |
| Sep 8, 26 | BTIG | maintain | Buy | Buy |
| Aug 12, 26 | Oppenheimer | upgrade | Perform | Outperform |
| Jul 30, 26 | HSBC | downgrade | Buy | Hold |
| Jul 17, 26 | Raymond James | maintain | Outperform | Outperform |
| Jul 17, 26 | Wells Fargo | maintain | Overweight | Overweight |
| Jul 17, 26 | TD Cowen | maintain | Buy | Buy |
| Jul 17, 26 | Evercore ISI Group | maintain | In Line | In Line |
| Jul 17, 26 | RBC Capital | maintain | Outperform | Outperform |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 10-Q | Oct 21, 2026 | 2026-10-21 17:14:21 | View |
| 8-K | Oct 20, 2026 | 2026-10-20 16:05:16 | View |
| 4 | Oct 13, 2026 | 2026-10-13 13:54:07 | View |
| 4 | Oct 13, 2026 | 2026-10-13 12:44:33 | View |
| 4 | Sep 16, 2026 | 2026-09-16 13:35:36 | View |
| 4 | Sep 11, 2026 | 2026-09-11 18:41:15 | View |
| 4 | Sep 9, 2026 | 2026-09-09 18:45:17 | View |
| 4 | Aug 21, 2026 | 2026-08-21 19:56:13 | View |
| 4 | Aug 19, 2026 | 2026-08-19 17:39:47 | View |
| 4 | Aug 12, 2026 | 2026-08-12 13:22:26 | View |
Proxy statement (DEF 14A) disclosures